Strategy & Portfolio Prioritization
Which programs deserve the next dollar?
The Problem We Solve
Emerging biotechs almost always have more good ideas than capital. The hard part isn't finding opportunities: it's choosing among them under a cash clock, with incomplete data and a management team that doesn't yet agree.
Our Strategy & Portfolio service brings a disciplined, analytically grounded process for deciding what to fund, what to defer, what to partner, and what to stop.
Deliverables:
Prioritized portfolio with full rationale
Indication selection and sequencing analysis
Commercial opportunity assessment
Tested launch assumptions
Probability-adjusted comparison across all programs
Development and partnering options evaluated together
Primary market research where stakes justify it
How it works
Step 1
Value
We value every program on the same probability-adjusted basis, a development program, an in-licensing candidate, a partnering opportunity, all measured the same way.
Step 2
Compare
Each option is measured on return per dollar invested and its capacity to create near-term value inflection.
Step 3
Integrate
We evaluate development and business-development options together, not in silos, the decision to advance an asset and the decision to partner it are the same decision.
YOUR EDGE
What a disciplined portfolio process creates
Every program judged on the same basis
Board and management align on one direction
Capital goes to the highest-return options
Development and partnering decided together, not separately
Launch assumptions tested before capital commits
Fewer programs funded on conviction alone
A portfolio you can defend under a cash clock
WHO THIS IS FOR
Companies with more good ideas than capital
This service is ideal for companies with more programs, or candidate indications, than their runway can support, where the board and management need a shared, defensible basis for what to fund, defer, or stop.
